CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


CPI-006Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)


Name (Synonyms) Correlation

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D001172 Arthritis, Rheumatoid NIH 0.38
D001168 Arthritis NIH 0.29

Correlated HPO Terms (2)


Name (Synonyms) Correlation
HP:0001370 Rheumatoid arthritis HPO 0.38
HP:0001369 Arthritis HPO 0.29

There is one clinical trial.

Clinical Trials


1 Immunotherapy of COVID-19 With B-Cell Activating CPI-006 Monoclonal Antibody

This Phase 1 single-dose, dose-escalation study is an open label trial evaluating the safety of CPI-006, a humanized monoclonal antibody targeting the CD73 cell-surface ectonucleotidase, as immunotherapy for stable hospitalized mild or moderately symptomatic COVID-19 patients.

NCT04464395 COVID-19 Drug: CPI-006

Primary Outcomes

Description: Incidence of adverse events (including serious adverse events and dose limiting toxicities).

Measure: Incidence of Treatment-Emergent Adverse Events to Determine Single Dose of CPI-006 That is Safe in Patients with COVID-19

Time: Up to 30 days after dose of CPI-006.

Description: Measure changes in serum or plasma immunoglobulin anti-SARS CoV-2 levels.

Measure: Immunoglobulin Anti-SARS CoV-2 Levels

Time: Baseline and Day 28.

Secondary Outcomes

Description: Time to two consecutive negative nasal swab PCR SARS CoV-2 viral tests.

Measure: Negative Nasal Swab Polymerase Chain Reaction (PCR) SARS CoV-2 Viral Tests

Time: Baseline to two consecutive negative nasal swab PCR SARS CoV-2 viral tests (separated by at least 48 hours).

Description: Duration of COVID-19 related symptoms.

Measure: Duration of symptoms

Time: Up to 24 weeks after dose of CPI-006.

Description: Time to discharge from hospital.

Measure: Time to discharge

Time: Up to 24 weeks after dose of CPI-006.

Description: Rate of medical procedures during hospitalization.

Measure: Rate of medical procedures

Time: Up to 24 weeks after dose of CPI-006.


No related HPO nodes (Using clinical trials)